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Background: Juvenile Fibromyalgia (JFM) is characterized by chronic widespread musculoskeletal pain and
approximately 40% of children and adolescents with JFM also suffer from benign joint hypermobility (HM). It is not
currently known if the presence of HM affects the pain experience of adolescents with JFM. The objective of this
study was to examine whether there were any differences in self-reported pain intensity and physiologic pain
sensitivity between JFM patients with and without joint HM.
Methods: One hundred thirty-one adolescent patients with JFM recruited from four pediatric rheumatology clinics
completed a daily visual analogue scale (VAS) pain rating for one week and underwent a standardized 18-count
tender point (TP) dolorimeter assessment. Medical records were reviewed for the presence of joint HM. Average
pain VAS ratings, tender point count and tender point sensitivity were compared between JFM patients with and
without hypermobility (HM+ and HM-).
Results: Nearly half (48%) the sample of JFM patients were found to be HM+. HM+ and HM- patients did not differ
in their self-reported pain intensity. However, HM+ patients had significantly greater pain sensitivity, with lower TP
thresholds (p = 0.002) and a greater number of painful TPs (p = 0.003) compared to HM- patients.
Conclusion: The presence of HM among adolescent patients with JFM appears to be associated with enhanced
physiologic pain sensitivity, but not self-report of clinical pain. Further examination of the mechanisms for increased
pain sensitivity associated with HM, especially in adolescents with widespread pain conditions such as JFM is
warranted.
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Juvenile fibromyalgia (JFM) is a chronic condition of
widespread musculoskeletal pain and fatigue in children
and adolescents. Prevalence estimates for JFM range
from 1-6% of the pediatric population [1,2]. While there
are often associated symptoms of poor sleep, fatigue,
and emotional distress in JFM, pain is the defining com-
ponent in the diagnosis of fibromyalgia (FM). The report
of diffuse pain for 3 or more months and severe pain in
multiple tender points upon palpation is required as part
of the classification criteria for FM by both Yunus and* Correspondence: tracy.ting@cchmc.org
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reproduction in any medium, provided the orMasi [3] and the 1990 American College of Rheumatol-
ogy (ACR) [4] criteria.
Benign joint hypermobility (HM) is a relatively more
common condition than JFM, with prevalence rates in
children and adolescents estimated to be up to 30% [5].
Children and adolescents with increased joint laxity have
been found to frequently suffer from chronic musculo-
skeletal pain complaints [5,6], although one large popu-
lation study indicated no such association [7]. Yet many
children with joint HM do not suffer from the full
spectrum of JFM symptoms. On the other hand, there
appears to be a much closer overlap among patients with
JFM and benign joint HM. In fact, two studies have
reported a higher prevalence of HM co-occurring with
JFM. One study found that 81% of Israeli JFM school-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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United States reported that 40% of JFM adolescents also
had HM [9]. In the adult literature, it has been suggested
that the presence of HM is associated with increased
pain in women with FM [10]. However, the relationship
between pain characteristics and HM has not been
examined in children and adolescents with JFM.
The underlying mechanisms for pain hypersensitivity
in FM have been extensively studied while the etiology
of pain in HM has received little attention. It has been
well documented that persons with FM have an overall
lower threshold for pain as demonstrated by increased
responsiveness and hypersensitivity to pain [11] in the
form of central sensitization and wind-up in response to
repeated noxious stimulation [12]. It is not currently
known whether joint laxity/HM is associated with
enhanced sensitization to pain in FM although it has
been suggested (though not proven) that repeated
microtrauma occurring among persons with abnormal
joint hyperextensibility might lead to persistent localized
pain [13].
As part of the screening for a larger clinical trial exam-
ining the effectiveness of cognitive-behavioral therapy
for JFM, we assessed baseline pain intensity and tender
point sensitivity (tender point count and tender point
threshold) of over 100 adolescents with JFM [14]. For
the current study, we reviewed patients’ medical charts
to determine the frequency of benign joint HM as deter-
mined by their treating rheumatologist. The primary
objectives of this study were to examine the prevalence
of HM in this clinical sample of adolescents with JFM
and to compare the pain experience between JFM
patients with joint HM (HM+) and without (HM-).
Based upon previous studies, it was anticipated that at
least 40% of JFM patients would be HM+ [2,5,6,15]. We
also hypothesized that JFM patients who were HM+
would report higher clinical pain intensity (based upon
self-report) and demonstrate enhanced pain sensitivity




Participants were 131 adolescents (92.4% female, 89.3%
Caucasian) with JFM between the ages of 11 and 18 years
(mean age = 15.1 years) who were initially screened for
the parent clinical trial. Participants were recruited from
four pediatric rheumatology clinics (six total pediatric
rheumatologists) in Ohio and Kentucky, with each site
having Institutional Review Board approval. All partici-
pants met Yunus and Masi criteria [3] adapted for JFM
classification which includes: generalized musculoskel-
etal aching for greater than three months, the presence
of at least 5 out of 18 tender points, and at least threeassociated symptoms such as poor sleep quality, fatigue,
chronic anxiety, irritable bowel syndrome or chronic
headaches. Participants had to have an average pain in-
tensity of at least 4 (on a 0-10 cm visual analog scale,
VAS) to be eligible for the trial and were excluded if they
had other chronic rheumatic diseases such as juvenile
idiopathic arthritis or systemic lupus erythematosus or
other comorbid illness that could cause fibromyalgia-like
symptoms (e.g. thyroid disease).Procedure
Participants were informed of the study by their primary
rheumatologist and contacted by a research assistant for
their interest in participation. Written informed consent
from parents and assent from adolescents was obtained.
Participants were asked to complete a daily pain diary
for the week prior to the initial evaluation. All partici-
pants were formally evaluated by a pediatric rheumatolo-
gist with a complete medical history and physical
examination.Measures
Demographic information
A demographic form regarding the participant’s age, sex,
race and ethnicity was completed by the parent(s).Tender point assessment (pain sensitivity)
An 18-count TP examination, as described in the ACR
criteria for FM [4], was performed by a trained pediatric
rheumatologist. A dolorimeter (Pain Diagnostics &
Treatment Inc., Great Neck, NY) with a 1 cm rubber tip
was applied at a rate of 1 kg/cm2 of pressure per second.
The participant was asked to inform the evaluator the
point at which pain (not pressure) was felt and this pain
threshold, from 1 to> 4 kg/cm2, was noted for each of
the 18 TP sites. An average TP score (pain threshold)
based upon the 18 points was calculated, with lower
scores indicating greater pain sensitivity. The total num-
ber of positive (score of< 4 kg/cm2) painful TPs was
also recorded.Pain rating (VAS)
For one week prior to their assessment visit, adolescents
completed a diary rating of their average level of pain
each day using a Visual Analog Scale (VAS, 10 cm hori-
zontal line with no numerical markings). VAS scales [16]
are well-validated and widely used in pediatric pain re-
search [17]. The pain VAS scale was anchored with the
descriptors of 0 = “no pain” and 10 = “worst possible
pain”. The average pain rating over the period of one
week of daily diaries was used as a measure of self-
reported clinical pain intensity.
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Medical charts were reviewed for participant informa-
tion regarding physical exam findings, including joint
HM. HM was defined by each individual clinician’s as-
sessment of increased joint laxity (HM noted to be
present if found in at least 4 joints). For this preliminary
clinical observational study, information about specific
standardized criteria for HM (such as Beighton scores)
was not available due to variability in clinical documen-
tation in medical records at each site. However, all
examining physicians were board certified/eligible
pediatric rheumatologists who are trained to use similar
criteria for classification of HM in children. Each of the
6 pediatric rheumatologists indicated they used either
the Beighton [18] or Carter and Wilkinson [19] criteria
(Table 1) for joint hypermobility and documented hyper-
mobility if they met criteria.Statistical analyses
All data were entered and analyzed using SPSS Version
15.0 software. Descriptive data on pain VAS scores,Table 1 Criteria for Joint Hypermobility
Criteria Definition Scoring
Beighton [18] Passive hyperextension ≥10
degrees of the knee
Right – 1 point
Left –1 point
Passive hyperextension ≥10
degrees of the elbow
Right – 1 point
Left – 1 point
Passive apposition of the thumb
to the flexor aspect of the forearm
Right – 1 point
Left – 1 point
Passive dorsiflexion of 5th finger
metacarpophalangeal joint to≥ 90o
Right – 1 point
Left – 1 point
Forward flexion of the trunk,
with the knees straight,
so that the palms rest easily
and flat on the floor
1 point





of the thumb to
the flexor aspect of the forearm
1 point
Bilateral passive hyperextension




of the elbows> 10o
1 point
Passive hyperextension




and excessive foot eversion
1 point
**A score of 3/5 or greater equates hypermobilityaverage TP sensitivity (TP threshold score) and number
of painful tender points (TP count) were computed.
Pearson correlation coefficients were computed to assess
the relationship between average VAS pain score, aver-
age TP score, and TP count. Average pain VAS and TP
scores were compared between the HM+and HM-
groups using t-tests, and TP counts in the HM+ versus
HM- groups were compared using the non-parametric
Mann-Whitney test (due to non-normal distributed data
on TP counts).
Results
Self-reported pain and pain sensitivity
Among the 131 participants, the mean pain rating as
measured by daily diaries on a 10-point VAS was 5.73
(SD 1.37). The mean TP count among all participants
was 16.23 (SD 2.30) with 85% having 14 or more positive
TPs. The mean TP score was 2.26 kg/cm2 (SD 0.58)
(Table 2). Among the 18 TP sites, TP locations with the
lowest mean pain threshold were in the head and neck
region (anterior rib, low cervical, and occiput) with
lower average thresholds consistently seen among the
HM group (Figure 1A/B). In correlations between self-
reported VAS and pain sensitivity measures based upon
dolorimetry, neither TP score (Pearson r = -0.08) nor TP
count (Spearman ρ= 0.06) was significantly associated
with VAS self-report of pain intensity (Table 3).
Role of hypermobility in the pain experience
Documentation of HM was available for 95% (122/131)
of participants. Of the 122 JFM patients, nearly half
(48%, n = 58) were noted by their primary rheumatolo-
gist to have hypermobile joints. Mean self-reported VAS
in the HM+group was 5.59 (SD 1.41) compared to 5.79
(SD 1.28) in the HM- group (p = 0.42, not significant).Table 2 Demographic information and mean pain scores
(self-report VAS, tender point total and scores)
Characteristic Mean SDa Range
Age (years) 15.08 1.81 11-18
VASb Rating (0-10) 5.73 1.37 1.16-8.86
Number of Positive Tender Pointsc (0-18) 16.23 2.30 9-18






Black or African-American 9 6.9
Other 5 3.8
a SD – standard deviation, b VAS – Visual Analogue Scale, c A positive tender





















Figure 1 a. Tender point averages in JFM patients without joint HM. b. Tender point averages in JFM patients with joint HM. Legend
Figure 1 a/b. Distribution of mean threshold scores (kg/cm2) by tender point location. Mean tender point scores are noted for each of the 18 tender
point sites. R: Right, L: Left, 1. Low Cervical, 2. Anterior Rib, 3. Lateral Epicondyle, 4. Medial Fat Pad, 5. Occiput, 6. Trapezius, 7. Supraspinatus, 8.
External Outer Gluteal, 9. Greater Trochanter.
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pain sensitivity with lower mean TP scores (2.10 kg/cm2
vs. 2.41 kg/cm2, p = 0.002) and higher TP count (16.77
vs. 15.72, p = 0.003) than HM- patients (Table 4).
Discussion
Fibromyalgia syndrome in adolescents is characterized
by chronic widespread musculoskeletal pain and mul-
tiple associated symptoms. Consistent with prior reports
[8,9], results of this study showed that joint HM com-
monly co-occurs with JFM in children and adolescents
with nearly half of the adolescents with JFM also having
HM. This is similar to findings from adult fibromyalgiastudies which have reported that 46.6% [20] to 62% [10]
of fibromyalgia patients also had HM. In addition to rep-
licating findings regarding the overlap between JFM and
HM, results of this study suggest the possibility that a
‘benign’ condition like joint laxity can be associated with
enhanced pain sensitivity in JFM patients. Specifically,
HM+patients show significantly greater physiologic sen-
sitivity as measured by TP threshold and TP count than
HM- patients, even though their self-report of clinical
pain intensity did not differ. However, it is unclear if this
difference is clinically relevant as all patients had rela-
tively high pain sensitivity. Interestingly, all tender point
locations were lower among the HM+group and not
Table 4 Relationship of mean VAS score, tender point
count and tender point score among JFM patients with
or without joint hypermobility
Hypermobility No Hypermobility
Mean Mean Pb CIc
VASa Rating 5.59 5.79 0.42 −2.92 – 0.68
Tender Point Count 16.77 15.72 0.003 −1.9 – -0.24
Tender Point Score 2.10 2.41 0.002 0.12 – 0.52
a VAS – Visual Analogue Scale, b – Significant p-value <0.05, c – Confidence
Interval.
Table 3 Correlation analysis of the relationship between







Tender Point Score 1 −0.84b −0.08
Tender Point Count −0.84b 1 0.06
VASa Rating −0.08 0.06 1
a VAS – Visual Analogue Scale, b p-value <0.001.
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ible (i.e. knees).
Potential mechanisms underlying the relationship be-
tween HM and pain sensitivity in JFM patients might in-
clude genetic vulnerability associated with gene
polymorphisms responsible for pain perception [21]
[22], immunologic factors [23], or related to the com-
mon features of dysautonomia (syncope, orthostatic
hypotension, tachycardia, etc.) often reported by both
HM and JFM patients [24,25]. Interestingly, despite the
evidence of increased pain sensitivity in JFM HM+ ado-
lescents, we found that the subjective report of clinical
pain (VAS pain ratings) did not correlate with physio-
logic pain sensitivity. Furthermore, there was no signifi-
cant difference in clinical pain reports between JFM
adolescents with and without HM. These results
reinforce the notion that pain is a complex subjective
multidimensional experience. Results obtained from dif-
ferent assessment methods (subjective pain ratings ver-
sus sensory testing) may therefore represent different
facets of pain.
The results of this study have implications for the
measurement of pain outcomes in clinical trials of JFM.
In recent studies, cognitive behavioral therapy (CBT)
has been found to be a promising treatment for JFM
[26,27] and the parent clinical trial associated with this
study showed that CBT was effective in reducing pain-
related disability and depressive symptoms. Patients also
reported reduced pain intensity (VAS) levels, but there
was no change in tender point sensitivity after CBT. In
order to change physiologic pain sensitivity, other types
of interventions, for example, intensive aerobic exercise
programs, which have been shown to be effective for
pain reduction [28] need to be further studied. Tailored
programs for JFM HM+ children focusing on joint pro-
tection and strengthening might also be investigated to
see if they can produce reductions in mechanical stress
which could ameliorate heightened pain sensitivity.
We recognize several limitations of our study. Our
patients were recruited from tertiary pediatric rheuma-
tology clinics; therefore, they may represent the most se-
vere and prolonged cases of JFM. The majority of
patients (85%, n = 112) had a total of >14 positive TPand nearly half (47%) had 18/18 positive TP. Another
limitation is that the scoring systems for HM (i.e.
Beighton, Brighton, Carter and Wilkinson) were not
strictly standardized in our study; however, each
rheumatologist indicated they documented hypermobi-
lity if a patient met criteria. Despite the potential recruit-
ment of patients with more severe JFM and the non-
standardized clinician assessment of HM, the prevalence
of HM in this sample was found to be similar to that
reported by Siegel and colleagues, i.e., almost half of the
JFM sample [9].
Conclusions
The findings of this study strengthen prior reports of joint
HM being commonly observed among clinical popula-
tions of adolescent JFM patients. Additionally, we found
that HM is associated with heightened pain sensitivity.
Suggestions for future research include identifying the
genetic link(s) attributable to these associated conditions,
continued physiological assessments to better understand
the mechanisms of pain in both HM and JFM, and evalu-
ation of targeted exercise programs for this population. A
greater understanding of the various aspects of pain in
JFM is needed to further enrich the multidisciplinary ap-
proach for treatment of this complex syndrome.
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